Opigolix
Jump to navigation
Jump to search
Clinical data | |
---|---|
Other names | ASP-1707 |
Routes of administration | By mouth |
Drug class | GnRH modulator; GnRH antagonist; Antigonadotropin |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C25H19F3N4O5S |
Molar mass | 544.51 g·mol−1 |
3D model (JSmol) | |
| |
|
Opigolix (INN , USAN ; developmental code name ASP-1707) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which was under development by Astellas Pharma for the treatment of endometriosis and rheumatoid arthritis.[1][2] It was also under investigation for the treatment of prostate cancer.[1] It reached phase II clinical trials for both endometriosis and rheumatoid arthritis prior to the discontinuation of its development in April 2018.[1]
See also
References
- ^ a b c "Opigolix - Astellas Pharma - AdisInsight".
- ^ Ezzati M, Carr BR (2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Women's Health. 11 (1): 19–28. doi:10.2217/whe.14.68. PMID 25581052.
External links
Categories:
- Articles with short description
- Short description matches Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Abandoned drugs
- Secondary alcohols
- Amidines
- Benzimidazoles
- Fluoroarenes
- GnRH antagonists
- Aromatic ketones
- All stub articles
- Genito-urinary system drug stubs